Navigation Links
Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009
Date:9/10/2009

racyclines: A Novel Class of Tetracycline Analogs

  • Presentation Number F1-1515: In Vitro and In Vivo Activities of Novel Broad-Spectrum 8-Aza Tetracyclines

  • Presentation Number F1-1516: Synthesis and Antibacterial Activities of Pentacyclines: A Novel Class of Tetracycline Analogs

Copies of the oral presentation and the posters will be available at ICAAC and on the Tetraphase website (www.tphase.com) following ICAAC.

About Tetraphase Pharmaceuticals Inc.

Tetraphase Pharmaceuticals is capitalizing on breakthrough synthetic chemistry technology for drug discovery and development based on a process developed by world-leading organic chemist Dr. Andrew Myers of Harvard University. This enabling advance in chemistry provides the company with a broad range of commercial opportunities across a number of significant disease categories.


'/>"/>
SOURCE Tetraphase Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PharmAthene Presents Data for Valortim(R) Anthrax Anti-Toxin and Third Generation rPA Anthrax Vaccine Programs at the Bacillus - ACT 2009 Conference
2. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
3. iSEEK Enterprise Presents Collaboration with Penn Medicine at 2009 AMEE Conference
4. Viral Genetics Scientist Presents Potential New Treatment for Drug Resistant Brain Tumors at Aspen Symposium
5. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association
7. Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions
8. Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress
9. Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions
10. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
11. Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014  Pfenex Inc. (NYSE MKT: PFNX), ... of high-value and difficult to manufacture proteins including ... reported financial results for the second quarter ended ... completion of our initial public offering, we have ... product candidates, derived from our proprietary protein expression ...
(Date:8/29/2014)... 29, 2014 The global companion ... in 2019. It is expected to grow at ... and was valued at $1.8 billion in 2013, ... Market Research. , For more information regarding analysis ... , The research report, titled “Companion Diagnostics Market ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... Chairman, Hub MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, ... JASIS on September 5, 2014. JASIS , Asia’s ... September 3-5, 2014, in Makuhari Messe, Japan. , ... New Tools for Bioanalysis from Single Molecules to Single ...
(Date:8/29/2014)... 2014 Local veterinarian, Dr. Keith Clement, ... seeking candidates to participate in an investigational study of ... ultimate goal of this study is to determine if ... or two arthritically affected joints can help reduce pain ... for the current investigational study must be older than ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2
... today its financial results for the year ending 31,December 2008. , , ... regulatory process for intravenous iclaprim in US, - ... of "intravenous-to-oral" Phase II trial with oral, ... - Share placing, Cash and financial investments of ...
... better restaurant menu optionsINDIANAPOLIS, Feb. 25 This year,s ... America with the reduction of nearly a half billion ... three years. Since the market introduction in 2006, Omega-9 ... replaced more than 340 million pounds of trans fat, ...
... collaborative agreement with CureDM to continue the preclinical development of CureDM,s HIP2B ... , ... Cary, NC (PRWEB) February 25, 2009 -- Calvert ... the signing of a collaborative agreement with CureDM to continue ...
Cached Biology Technology:Arpida Announces Full Year 2008 Financial Results 2Arpida Announces Full Year 2008 Financial Results 3Arpida Announces Full Year 2008 Financial Results 4Arpida Announces Full Year 2008 Financial Results 5Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 2Heart Health Month Milestone: Half a Billion Pounds of Bad Fats Eliminated From North American Diet 3Calvert Research and CureDM Sign Collaborative Agreement 2Calvert Research and CureDM Sign Collaborative Agreement 3
(Date:9/2/2014)... accidentally touch a hot oven, you rapidly pull your ... involved in sensing and responding to such painful stimuli, ... Duke researchers have made a surprising discovery about the ... worms, and have built a structural model of the ... Communications , may help direct new strategies to treat ...
(Date:9/1/2014)... ─ Dietary quality in the U.S. has improved steadily ... fat intakebut overall dietary quality remains poor and disparities ... to a new study from Harvard School of Public ... evidence to date that the extensive efforts by many ... having some payoff, but it also indicates that these ...
(Date:9/1/2014)... Within minutes after birth, every child in the U.S. ... host of conditions, including sickle cell disease. Thousands of ... lucky, meaning many suffer and die from the disease ... a halt to at least some of those deaths. ... Biology working in the lab of George Whitesides, the ...
Breaking Biology News(10 mins):Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Faster, cheaper tests for sickle cell 2Faster, cheaper tests for sickle cell 3
... connection between the body, mind and spirit has been ... years. The notion that psychosocial and societal considerations have ... crystallized as a result of the experiences of a ... writer and magazine editor of the popular Saturday Review, ...
... / b3c newswire / - Addressing significant product safety and ... has announced the commercial launch of two protease-free ... Albumin-DX (Lipid-Free) perform better in diagnostics applications than ... serum albumin (pHSA).  , , ...
... is a tragic disease that robs an individual of their memory ... 65 now suffer from the disease and one in two people ... Alzheimer,s does not only affect the elderly. Familial Alzheimer,s disease (FAD), ... The Study , Alzheimer,s is a complex ...
Cached Biology News:Laughter remains good medicine 2Laughter remains good medicine 3InVitria Announces Launch of Recombinant Albumin for Diagnostics 2Computational model examines the pathways of Alzheimer's that strikes at the young 2
Mouse monoclonal antibody raised against a partial recombinant DENR. NCBI Entrez Gene ID = DENR...
Mouse monoclonal antibody raised against a partial recombinant CRKRS. NCBI Entrez Gene ID = CRKRS...
... BD PhosFlow Perm/Wash Buffer I can be ... signaling proteins to permeabilize cells and to ... wash buffer. Because saponin-mediated cell permeabilization is ... keep the cells in the presence of ...
Mouse monoclonal antibody raised against a full length recombinant GPT. NCBI Entrez Gene ID = GPT...
Biology Products: